Wu KC - Search Results

1

PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR.

Jiang Y, Lim J, Wu KC, Xu W, Suen JY, Fairlie DP. Jiang Y, et al. Among authors: wu kc. Br J Pharmacol. 2021 Feb;178(4):913-932. doi: 10.1111/bph.15332. Epub 2020 Dec 30. Br J Pharmacol. 2021. PMID: 33226635 Free article.

2

Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2.

Xu W, Lim J, Goh CY, Suen JY, Jiang Y, Yau MK, Wu KC, Liu L, Fairlie DP. Xu W, et al. Among authors: wu kc. J Chem Inf Model. 2015 Oct 26;55(10):2079-84. doi: 10.1021/acs.jcim.5b00500. Epub 2015 Oct 12. J Chem Inf Model. 2015. PMID: 26445028

3

Biased Signaling by Agonists of Protease Activated Receptor 2.

Jiang Y, Yau MK, Kok WM, Lim J, Wu KC, Liu L, Hill TA, Suen JY, Fairlie DP. Jiang Y, et al. Among authors: wu kc. ACS Chem Biol. 2017 May 19;12(5):1217-1226. doi: 10.1021/acschembio.6b01088. Epub 2017 Mar 14. ACS Chem Biol. 2017. PMID: 28169521

4

Europium-Labeled Synthetic C3a Protein as a Novel Fluorescent Probe for Human Complement C3a Receptor.

Dantas de Araujo A, Wu C, Wu KC, Reid RC, Durek T, Lim J, Fairlie DP. Dantas de Araujo A, et al. Among authors: wu c, wu kc. Bioconjug Chem. 2017 Jun 21;28(6):1669-1676. doi: 10.1021/acs.bioconjchem.7b00132. Epub 2017 May 31. Bioconjug Chem. 2017. PMID: 28562031

5

Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a.

Lohman RJ, Hamidon JK, Reid RC, Rowley JA, Yau MK, Halili MA, Nielsen DS, Lim J, Wu KC, Loh Z, Do A, Suen JY, Iyer A, Fairlie DP. Lohman RJ, et al. Among authors: wu kc. Nat Commun. 2017 Aug 24;8(1):351. doi: 10.1038/s41467-017-00414-w. Nat Commun. 2017. PMID: 28839129 Free PMC article.

6

A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells.

Jiang Y, Yau MK, Lim J, Wu KC, Xu W, Suen JY, Fairlie DP. Jiang Y, et al. Among authors: wu kc. J Pharmacol Exp Ther. 2018 Feb;364(2):246-257. doi: 10.1124/jpet.117.245027. Epub 2017 Dec 20. J Pharmacol Exp Ther. 2018. PMID: 29263243

7

Bicyclic Helical Peptides as Dual Inhibitors Selective for Bcl2A1 and Mcl-1 Proteins.

D de Araujo A, Lim J, Wu KC, Xiang Y, Good AC, Skerlj R, Fairlie DP. D de Araujo A, et al. Among authors: wu kc. J Med Chem. 2018 Apr 12;61(7):2962-2972. doi: 10.1021/acs.jmedchem.8b00010. Epub 2018 Mar 27. J Med Chem. 2018. PMID: 29584430

8

Potent Thiophene Antagonists of Human Complement C3a Receptor with Anti-Inflammatory Activity.

Rowley JA, Reid RC, Poon EKY, Wu KC, Lim J, Lohman RJ, Hamidon JK, Yau MK, Halili MA, Durek T, Iyer A, Fairlie DP. Rowley JA, et al. Among authors: wu kc. J Med Chem. 2020 Jan 23;63(2):529-541. doi: 10.1021/acs.jmedchem.9b00927. Epub 2020 Jan 7. J Med Chem. 2020. PMID: 31910011

9

Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation.

Tng J, Lim J, Wu KC, Lucke AJ, Xu W, Reid RC, Fairlie DP. Tng J, et al. Among authors: wu kc. J Med Chem. 2020 Jun 11;63(11):5956-5971. doi: 10.1021/acs.jmedchem.0c00230. Epub 2020 May 21. J Med Chem. 2020. PMID: 32383881

10

HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.

Mak JYW, Wu KC, Gupta PK, Barbero S, McLaughlin MG, Lucke AJ, Tng J, Lim J, Loh Z, Sweet MJ, Reid RC, Liu L, Fairlie DP. Mak JYW, et al. Among authors: wu kc. J Med Chem. 2021 Feb 25;64(4):2186-2204. doi: 10.1021/acs.jmedchem.0c01967. Epub 2021 Feb 11. J Med Chem. 2021. PMID: 33570940

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

932 results

Search Page

Filters